Cartesian Therapeutics RNAC
NASDAQ RNAC
$6.41 -0.01 (-0.16%)
At close: Oct 22, 2026 · 4:00 PM EDT

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023)

Updated

Cartesian Therapeutics (RNAC) posted Preferred Stock Liabilities of $296.85 million for Q4 2023.

Analysis

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023) Analysis & Trends

  • The Q4 2023 figure stands as the lowest quarterly Preferred Stock Liabilities since Q2 2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Cartesian Therapeutics 192.54 Mn -342.23 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 296.85 Mn
Jun 30, 2016 5.00 Mn
Dec 31, 2015 137.48 Mn
API Access

Cartesian Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RNAC&period=max&api_key=YOUR_API_KEY